Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyJames F. Howard, Daniel Ambrosio, Ted M. Burns et al.|The Lancet Neurology|2017Cited by 820
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label ExtensionRenato Mantegazza, Maria da Penha Ananias Morita, Gil I. Wolfe et al.|Neurology|2020Cited by 80
Eculizumab improves fatigue in refractory generalized myasthenia gravisHenning Andersen, Érica Nogueira Coelho, Renato Mantegazza et al.|Quality of Life Research|2019Cited by 58
Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension studyHiroyuki Murai, Luiz Augusto da Silva, Akiyuki Uzawa et al.|Journal of the Neurological Sciences|2019Cited by 23